AI could predict who responds to esophageal cancer therapy
NCT ID NCT07063901
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses artificial intelligence to analyze patient data—like medical history, scans, and lab results—to predict how well esophageal cancer patients respond to chemoimmunotherapy before surgery. Researchers aim to build a model that identifies who achieves a complete response and who may need a different approach. The study involves 200 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors identify which patients benefit most from chemoimmunotherapy before surgery, avoiding ineffective treatments.
What could go wrong
This is an observational study, not a treatment trial. The AI model may not be accurate enough for real-world use, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, 410011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••